Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- New York-Presbyterian Westchester Hospital — Bronxville, New York
- New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Glens Falls Hospital — Glens Falls, New York
- Northwell Health Cancer Institute at Huntington — Greenlawn, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- Maimonides Medical Center — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in New York: - Mount Sinai Queens — Astoria, New York
- Northwell Health Imbert Cancer Center — Bay Shore, New York
- Lourdes Hospital — Binghamton, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- Nyack Hospital — Nyack, New York
- Stony Brook University Medical Center — Stony Brook, New York
- Dickstein Cancer Treatment Center — White Plains, New York
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in New York: - Mount Sinai Queens — Astoria, New York
- Glens Falls Hospital — Glens Falls, New York
- Garnet Health Medical Center — Middletown, New York
- Mount Sinai Union Square — New York, New York
- Mount Sinai Chelsea — New York, New York
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in New York: - NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- The Cancer Institute at Saint Francis Hospital — East Hills, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Mount Sinai Chelsea — New York, New York
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in New York: - Kings County Hospital Center — Brooklyn, New York
- Hematology Oncology Associates of Central New York, PC — East Syracuse, New York
- Cayuga Medical Center — Ithaca, New York
- NYU Langone Hospital-Long Island — Mineola, New York
- The Blavatnik Family - Chelsea Medical Center at Mount Sinai — New York, New York
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in New York: - NYOH Albany Cancer Center — Albany, New York
- New York University (NYU) Brooklyn — Brooklyn, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- NYC Health + Hospitals / Bellevue — New York, New York
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New York: - New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Babylon) — Babylon, New York
- NYU Langone's Perlmutter Cancer Center — Manhattan, New York
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(New Hyde Park) — New Hyde Park, New York
- Manhattan Hematology /Oncology Associates — New York, New York
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (NY) — New York, New York
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in New York: - The Blavatnik Family ? Chelsea Medical Center at Mount Sinai — New York, New York
- Mount Sinai West — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- New York Cancer & Blood Specialists — Shirley, New York
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in New York: - Clinical Trial Site — New York, New York
- Clinical Trial Site — New York, New York
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in New York: - Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in New York: - The Blavatnik Family - Chelsea Medical Center at Mount Sinai — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in New York: - NYU Langone Medical Center — New York, New York
- Columbia University Medical Center — New York, New York
Phase 3 Recruiting Industry
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Sponsor: AstraZeneca
NCT ID: NCT07205822
Sites in New York: - Research Site — New York, New York
Phase 3 Recruiting Academic/Other
This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will …
Sponsor: Weill Medical College of Cornell University
NCT ID: NCT06960707
Sites in New York: - Brooklyn Methodist Hospital — New York, New York
- New York Presbyterian Hospital — New York, New York
- New York-Presbyterian Weill Cornell Medical College — New York, New York
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in New York: - New York University Langone Hospital -Brooklyn — Brooklyn, New York
- New York University Langone Hospital - Long Island — Mineola, New York
- New York University Langone Health — New York, New York
- Northwell University — New York, New York
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in New York: - University of Rochester Medical Center — Rochester, New York
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in New York: - Mount Sinai Union Square — New York, New York
- Mount Sinai Chelsea — New York, New York
- Mount Sinai West — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in New York: - NYU Langone Health — New York, New York
- Icahn School of Medicine At Mount Sinai Prime — New York, New York
- Clinical Research Alliance, Inc — Westbury, New York
- White Plains Hospital — White Plains, New York
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in New York: - Research Site — Commack, New York
- Research Site — New York, New York